LYPD3 and lung cancer: In contrast to our findings of lower relative protein expression in relation arsenic exposure, enhanced protein expression of LYPD3 has been identified in tissues from urothelial cancers (59), breast cancers (60), melanoma (61), and lung cancers (62).